Genmab — Juni 2018
-
-
Bluebird bio cc : http://investor.bluebirdbio.com/events/event-details/asco-annual-meeting
-
-
Er det gode eller dårlige nyheder fra Bluebird?
-
bb2121 med Claus H Johansens kommentar. PFS på 11.8 mdr.
-
-
bb2121 median PFS var fra denne tweet https://twitter.com/myeloma_doc/status/1002681529309519872?s=21
-
Bluebird sluttede med at falde 5,02% i afterhours trading, efter at have lukket i + 3,35% i normal handel https://finance.yahoo.com/quote/BLUE?p=BLUE
-
Så det indikerer en skuffelse med bb2121 PFS på 11.8...?
-
Bluebird bb2121 delays progession by 1 year. But is it enough? https://twitter.com/adamfeuerstein/status/1002670789567696897?s=21
-
Bluebird not a cure https://twitter.com/matthewherper/status/1002674738420961281?s=21
-
-
CAR-T: median PFS 11,8 måneder. Det vil sige patienter der får behandlingen lever næsten 1 år. De er meget syge og har været igennem 7 andre behandlinger
-
De lever næsten 1 år som median inden sygdommen forværres igen
-
Darzalex i kombo med Kyprolis og dex. Respons i 84% af patienterne
-
Et år er ganske enkelt imponerende i så syge patienter, som har været igennem flere behandlingsforløb.
-
Dog ser jeg det ikke som en konkurrent til Dara, da Car-t er meget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind